DPP4 inhibitors: A new approach in diabetes treatment

Advances in Therapy

Volumn 25, Issue 7, 2008, Pages 627-643

  Doupis, John ^a   Veves, Aristidis ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Diabetes; Dipeptidyl peptidase IV; DPP4; Sitagliptin; Vildagliptin

Indexed keywords

ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; NITRILE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SITAGLIPTIN; TRIAZOLE DERIVATIVE; VILDAGLIPTIN;

ANIMAL; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; SECRETION;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; NITRILES; PYRAZINES; PYRROLIDINES; TRIAZOLES;

EID: 58149347643     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0076-1     Document Type: Review

References (74)

1. CDC web site. Diabetes and gestational diabetes trends among adults in the United States. Available at: www.cdc.gov. Accessed June 2008.
2. Zinman B. Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers. Diabetologia. 1997;40(suppl 2):S88-S90. (Pubitemid 27306928)
3. Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076-1082.
4. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954-1962.
5. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-2940. (Pubitemid 37205571)
6. Vilsboll T, Holst JJ. Incretins, insulin secretion and type-2 diabetes mellitus. Diabetologia. 2004;47:357-366. (Pubitemid 38491230)
7. Xu G, Stofers DA, Habener JF, et al. Exendin 4 stimulates both b-cell replication and neogenesis, resulting in increased b-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-2276. (Pubitemid 30395416)
8. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397-4408. (Pubitemid 35239574)
9. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36:804-810. (Pubitemid 40115903)
10. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin Effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52. (Pubitemid 16162741)
11. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84:3434-3438. (Pubitemid 17085418)
12. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21:517-533. (Pubitemid 350185859)
13. Nystrom T, Gutniak M, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type-2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-E1215. (Pubitemid 39491964)
14. Qi SY, Riviere PJ, Trojnar J, et al. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J. 2003;373:179-189. (Pubitemid 36819513)
15. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705. (Pubitemid 46048557)
16. Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs. 2007;16:533-545. (Pubitemid 46554470)
17. Byettal (exenatide) package insert. San Diego, CA: Amylin Pharmaceuticals; 2007.
18. Barnett A. Exenatide. Expert Opin Pharmacother. 2007;8:2593-2608. (Pubitemid 350031296)
19. Mikhail N. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J. 2006;99:1271-1279. (Pubitemid 44875853)
20. Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209-294. (Pubitemid 36775376)
21. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24. (Pubitemid 29505281)
22. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl peptidase I V, hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829-835. (Pubitemid 23188160)
23. Deacon CF, Johnson AH, Holst JJ. Degradation of glucagon-like hydrolyzes substance peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952-957.
24. Deacon CF, Nauck MA, Tof-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126-1131.
25. Deacon C F, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes diferential tissue-specifc metabolism in the anesthetized pig. Am J Physiol. 1996;271:E458-464.
26. Kiefer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585-3596.
27. Pauly RP, Rosche F, Wermann, et al. Biological Demuth H-U. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(3-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted Laser desorption/ionization-time of fight mass spectrometry. J Biol Chem. 1996;271:23222-23229 (Pubitemid 26314761)
28. Siegel EG, Gallwitz B, Scharf G, et al. Biological activity of GLP-1-analogues with N-terminal modifcations. Regul Pept. 1999;79:93-102. (Pubitemid 29376393)
29. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36)amide and comparison of the substrate specifcity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58:149-156.
30. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454-1470. (Pubitemid 44560347)
31. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-(3-hydroxy-1-adamantyl) amino-acetyl-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycaemic properties. J Med Chem. 2003;46:2774-2789. (Pubitemid 36702545)
32. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profle of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:5025-5037. (Pubitemid 41033142)
33. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-3-(trifuoromethyl)-5,6- dihydro1,2,4triazolo4,3-apyrazin-7(8H)-yl-1-(2,4,5-rifuorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141-151. (Pubitemid 40105255)
34. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695-1704. (Pubitemid 44324122)
35. Ahren B, Sorhede Winzell M, Burkey B, et al. Beta-cell expression of a dominant-negative HNF-1 alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol. 2005;521:164-168. (Pubitemid 41427804)
36. He YL, Sabo R, Campestrini J, et al. The infuence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol. 2007;63:677-686. (Pubitemid 46911348)
37. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic Effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46:876-886. (Pubitemid 44050824)
38. Ahren B, Gomis R, Standl E, et al. Twelve and 52-week efcacy of the dipeptidyl peptidase IV LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880. (Pubitemid 39565052)
39. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomised, placebo-controlled study in healthy male volunteers. Clin Ter. 2006;28:55-72. (Pubitemid 43254990)
40. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidyl peptidase-iv inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46:787-802. (Pubitemid 47347450)
41. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23:1329-1339. (Pubitemid 46998442)
42. Gallwitz B. Sitagliptin: profle of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:801-814.
43. Miller S, St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006;40:1336-1343. (Pubitemid 44204964)
44. Herman GA, Bergmann J, Wagner JA. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profle and the propensity for drug-drug interactions (DDI). Diabetologia. 2006;49:481.
45. Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22:1939-1947. (Pubitemid 44663399)
46. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycaemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-1987. (Pubitemid 47219404)
47. Miller JL, Migoya E, Talaty JE. The Effect of MK-0431 on the pharmacokinetics of digoxin afer concomitant administration for 10 days in healthy subjects. Clin Pharmacol Ter. 2006;79:24.
48. He Y-L, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47:633-641. (Pubitemid 46632151)
49. He YL, Sabo R, Balez S, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidyl peptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46:787-802. (Pubitemid 47347450)
50. Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide. Diabetes. 2004;53(suppl 2):470.
51. He YL, Sabo R, Picard F, et al. Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes. Clin Pharmacol Ter. 2006;79:62.
52. Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction. Diabetes. 2005; 54(suppl 1):528-529.
53. Hanefeld M, Herman G, Mickel C, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycaemic control afer 12 weeks in patients with type-2 diabetes. Diabetologia. 2005;49 (suppl 1):A287.
54. Scott R, Wu L, Sanchez M, et al. Effcacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type-2 diabetes. Int J Clin Pract. 2007;61:171-180.
55. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with type-2 diabetes. Diabetes Care. 2006;29:2632-2637. (Pubitemid 44912190)
56. Raz I, Hanefeld M, Xu L, et al. Efcacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type-2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
57. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomised trial. Diabetes Care. 2007;30:217-223. (Pubitemid 46198322)
58. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med. 2007;24:955-961. (Pubitemid 47301637)
59. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type-2 diabetes. J Clin Endocrinol Metab. 2004;89:2078-2084. (Pubitemid 38619835)
60. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692-698. (Pubitemid 41601073)
61. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efcacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type-2 diabetes. Diabetes Res Clin Pract. 2007;76:132-138. (Pubitemid 46240373)
62. Scherbaum WA, Schweizer A, Mari A, et al. Efcacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;Feb 1 Epub ahead of print.
63. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin of 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:186-193. (Pubitemid 46206562)
64. Charbonnel B, Karasik A, Liu J, et al. Efcacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643. (Pubitemid 44912191)
65. Rosenstock J, Brazg R, Andryuk PJ, et al. Sitagliptin Study 019 Group. Efcacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Clin Ter. 2006;28:1556-1568. (Pubitemid 44841980)
66. Jago C. American Diabetes Association. Updates on drug treatments-66th Scientifc Sessions 9-13 June 2006, Washington, DC, USA. IDrugs. 2006;9:538-541.
67. Hermansen K, Kipnes M, Luo E, et al. Efcacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733-745. (Pubitemid 47261855)
68. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type-2 diabetes over 1 year. Diabetes Care. 2005;28:1936-1940. (Pubitemid 41060966)
69. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function afer single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249-1255. (Pubitemid 46556394)
70. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazeone improves glycaemic control in patients with type-2 diabetes failing thiazolidinedione monotherapy: a randomised, placebo-controlled study. Diab Obes Metab. 2007;9:166-174. (Pubitemid 46206560)
71. Rosenstock J, Baron MA, Camisasca RP, Couturier A et al. Efcacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diab Obes Metab. 2007;9:175-185. (Pubitemid 46206561)
72. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008; Feb 18 Epub ahead of print.
73. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-1155. (Pubitemid 46701545)
74. Janumet (exenatide) package insert. Whitehouse Station, NJ: Merck & Co; 2008.